Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Sep;41(9):2033–2034. doi: 10.1128/aac.41.9.2033

In vitro activity of trovafloxacin against Chlamydia pneumoniae.

P M Roblin 1, A Kutlin 1, M R Hammerschlag 1
PMCID: PMC164061  PMID: 9303410

Abstract

The in vitro susceptibilities of 12 strains of Chlamydia pneumoniae to a new quinolone, trovafloxacin, and ofloxacin, doxycycline, erythromycin, and azithromycin were determined. The activity of trovafloxacin was similar to that of ofloxacin, with a MIC at which 90% of the isolates are inhibited and a minimal concentration at which 90% of the isolates are killed of 1.0 microg/ml, but trovafloxacin was less active than doxycycline, erythromycin, and azithromycin.

Full Text

The Full Text of this article is available as a PDF (148.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Block S., Hedrick J., Hammerschlag M. R., Cassell G. H., Craft J. C. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J. 1995 Jun;14(6):471–477. doi: 10.1097/00006454-199506000-00002. [DOI] [PubMed] [Google Scholar]
  2. Chirgwin K., Roblin P. M., Gelling M., Hammerschlag M. R., Schachter J. Infection with Chlamydia pneumoniae in Brooklyn. J Infect Dis. 1991 Apr;163(4):757–761. doi: 10.1093/infdis/163.4.757. [DOI] [PubMed] [Google Scholar]
  3. Crokaert F., Aoun M., Duchateau V., Grenier P., Vandermies A., Klastersky J. In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens. Eur J Clin Microbiol Infect Dis. 1996 Aug;15(8):696–698. doi: 10.1007/BF01691164. [DOI] [PubMed] [Google Scholar]
  4. Grayston J. T., Campbell L. A., Kuo C. C., Mordhorst C. H., Saikku P., Thom D. H., Wang S. P. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis. 1990 Apr;161(4):618–625. doi: 10.1093/infdis/161.4.618. [DOI] [PubMed] [Google Scholar]
  5. Hammerschlag M. R., Chirgwin K., Roblin P. M., Gelling M., Dumornay W., Mandel L., Smith P., Schachter J. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis. 1992 Jan;14(1):178–182. doi: 10.1093/clinids/14.1.178. [DOI] [PubMed] [Google Scholar]
  6. Hammerschlag M. R., Hyman C. L., Roblin P. M. In vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1992 Mar;36(3):682–683. doi: 10.1128/aac.36.3.682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hammerschlag M. R., Qumei K. K., Roblin P. M. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1992 Jul;36(7):1573–1574. doi: 10.1128/aac.36.7.1573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kenny G. E., Cartwright F. D. Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). Antimicrob Agents Chemother. 1996 Apr;40(4):1048–1049. doi: 10.1128/aac.40.4.1048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lipsky B. A., Tack K. J., Kuo C. C., Wang S. P., Grayston J. T. Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections. Am J Med. 1990 Dec;89(6):722–724. doi: 10.1016/0002-9343(90)90212-v. [DOI] [PubMed] [Google Scholar]
  10. Plouffe J. F., Herbert M. T., File T. M., Jr, Baird I., Parsons J. N., Kahn J. B., Rielly-Gauvin K. T. Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group. Antimicrob Agents Chemother. 1996 May;40(5):1175–1179. doi: 10.1128/aac.40.5.1175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Roblin P. M., Montalban G., Hammerschlag M. R. In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1994 Jun;38(6):1402–1403. doi: 10.1128/aac.38.6.1402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Teng R., Liston T. E., Harris S. C. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J Antimicrob Chemother. 1996 May;37(5):955–963. doi: 10.1093/jac/37.5.955. [DOI] [PubMed] [Google Scholar]
  13. Thomson K. S., Chartrand S. A., Sanders C. C., Block S. L. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae. Antimicrob Agents Chemother. 1997 Feb;41(2):478–480. doi: 10.1128/aac.41.2.478. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES